​

Lakewood-Amedex Biotherapeutics Stock (NASDAQ:LABT)


FinancialsChart

Previous Close

$0.40

52W Range

$0.17 - $98.20

50D Avg

$1.06

200D Avg

$6.83

Market Cap

$628.84K

Avg Vol (3M)

$15.07M

Beta

-4.76

Div Yield

-

LABT Company Profile


Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Apr 23, 2026

Website

LABT Performance


LABT Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income$-3.77M$-4.03M$-8.64M
Net Income$-3.85M$-4.86M$-8.28M
EBITDA$-3.63M$-4.73M$-8.15M
Basic EPS$-2.76$-6.94$-11.84
Diluted EPS$-2.76$-6.94$-11.84

Fiscal year ends in Dec 25 | Currency in USD